Vascular Disrupting Agents Market

How big is Vascular Disrupting Agents Market in 2026?

USD 0.8 billion in 2026 and USD 2.1 billion by 2036 at a 10.0% CAGR.

Demand for vascular disrupting agents is projected to expand at 10.0% CAGR between 2026 and 2036, increasing valuation from USD 0.8 billion in 2026 to USD 2.1 billion by 2036. The expansion Is supported by oncology drug development that links vascular shutdown with durable tumor control and repeat-dose safety.

Vascular-disruption programs rely on oncology trial infrastructure that can repeat imaging and safety assessments across dose cohorts. ClinicalTrials.gov reported in July 2026 that it listed 595,630 registered studies worldwide, including 454,529 interventional studies and 219,775 drug or biologic studies. The scale of registered interventional research supports recurring demand for monitored infusion, perfusion imaging and sequence-controlled combination protocols.

Key Takeaways

• Solid-tumor programs sustain demand for agents that damage established vessels and support sequence-specific combination treatment across difficult lesions.
• Tubulin-binding agents are projected at 48.0% share in 2026, driven by direct vascular effects and established clinical development history.
• Microtubule disruption is estimated at 52.0% of mechanism demand owing to rapid endothelial structural failure across abnormal tumor vessels.
• Oncology applications are forecast at 78.0% share in 2026, attributable to direct evaluation across solid tumors and metastatic cancer programs.
• Viable peripheral tumor cells and systemic vascular effects can limit durable response despite an immediate reduction in tumor perfusion.
• Oncotelic Therapeutics, Inc., BeyondSpring Inc., Neuphoria Therapeutics Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Sanofi and Abbott Laboratories.

Analyst Perspective

“A vascular-disrupting agent earns a larger trial through durable rim control alongside an acceptable repeat-dose cardiovascular profile. Sponsors should set perfusion thresholds and partner-therapy timing before dose expansion, so weak biological effects stop without consuming late-stage capital.”

- Anurag Sharma, Principal Consultant for Healthcare, Future Market Insights

How is the vascular disrupting agents market segmented?

The vascular disrupting agents industry is segmented by agent type, mechanism of action, application, route of administration, end user and region.

Agent type covers tubulin-binding, flavonoid-based, microtubule-independent, and other investigational agents across distinct chemical or platform families. Mechanism of action includes microtubule disruption, endothelial damage, blood-flow interruption, and other mechanisms used to damage established tumor vessels. Applications cover oncology, clinical research, and drug discovery while routes include intravenous, oral, and other administration across hospitals, drug developers, research institutes, contract research organizations, and seven geographic groups.

What supports demand for tubulin-binding vascular disrupting agents within the agent type category?

Abnormal tumor endothelial cells depend on an intact cytoskeleton to preserve vessel shape and blood flow during rapid tumor expansion. A current corporate filing provides direct market continuity: Oncotelic identified CA4P and OXi4503 as vascular disrupting agents under evaluation for further clinical development in April 2026.

• In 2026, tubulin-binding vascular disrupting agents are expected to lead agent type with 48.0% share because combretastatin derivatives provide the deepest direct clinical history.
• Research teams can track perfusion loss and central necrosis through established pharmacodynamic endpoints during early studies. Drug discovery services then compare those effects with viable-rim survival and dose tolerance across sequence-controlled combination programs.

How does microtubule disruption influence selection within the mechanism of action category?

Microtubule disruption links compound exposure directly with endothelial structural failure across abnormal tumor vessels during controlled oncology dosing. Unlike VEGF inhibitors that restrict new-vessel signaling, this mechanism attacks the established vascular architecture supporting an active lesion.

• The mechanism of action category is forecast to be led by microtubule disruption at 52.0% share in 2026 due to its rapid vascular shutdown mechanism.
• Trial teams need repeat-dose evidence that separates vascular effect from systemic toxicity across combination regimens. Oncotelic reported in April 2026 that transient hypertension associated with CA4P and OXi4503 had been managed through antihypertensive pretreatment during clinical evaluation.

What makes oncology central to the application category?

Oncology provides the direct setting for testing whether vascular shutdown improves tumor control beyond an early imaging response. Late-stage programs require multicenter networks that compare survival against a standard regimen across consistent imaging schedules. BeyondSpring reported in March 2026 that DUBLIN-3 enrolled 559 patients across 58 participating clinical sites.

• The oncology segment is likely to capture 78.0% share in 2026 attributable to combination needs across solid tumors and metastatic cancer.
• Imaging-equipped cancer centers compare vascular disruption with next-generation immunotherapies or cytotoxic regimens targeting surviving tumor cells. The comparison determines whether a temporary perfusion change contributes to durable lesion control across repeated treatment cycles.

What role does intravenous administration play within the route of administration category?

Intravenous dosing gives oncology teams direct control over infusion rate and systemic exposure during imaging-led protocols. The DUBLIN-4 registry posted in January 2026 specifies intravenous plinabulin on days one and eight, illustrating how route choice fixes observation and sequencing requirements.

• Intravenous administration is projected to hold 74.0% share in 2026 owing to controlled exposure and immediate safety support within specialist cancer centers.
• Research pharmacies coordinate dose escalation with imaging schedules and predefined observation periods across major specialist oncology centers. Their handling of injectable drugs supports repeatable preparation and rapid intervention during multicenter combination protocols.

What are the drivers, restraints and opportunities in the vascular disrupting agents market?

Solid-tumor programs need vascular shutdown that complements treatment of surviving cells despite repeat-dose limits from viable-rim recovery and systemic toxicity.

• Driver: Established tumor vessels provide a direct treatment target across solid cancers with uneven cellular sensitivity and prior treatment exposure.
• Restraint: Peripheral tumor cells can remain perfused, while cardiovascular and neurologic effects can restrict repeat-dose exposure across planned cycles.
• Opportunity: Perfusion thresholds and timed partner therapy can connect vascular response with durable lesion control during sequence-specific trials.

Vascular disruption targets established tumor blood flow and does not depend on uniform tumor-cell sensitivity. Global cancer statistics published by the American Cancer Society in July 2026 estimated nearly 21 million new cancer diagnoses and 9.8 million cancer deaths worldwide in 2024, with cases projected to reach 34 million by 2050. Clinical supply services preserve partner-drug timing and monitored dosing so cytotoxic or immune therapy reaches the surviving tumor compartment during the planned sequence.

Central vessel collapse can leave a viable peripheral rim that continues receiving blood from surrounding normal tissue. Repeat dosing can also expose cardiovascular and neurologic risks that narrow the usable treatment window. Oncology research organizations therefore need serial perfusion imaging, cardiac monitoring and predefined stopping rules for every expansion cohort.

Dynamic perfusion imaging can identify the exposure that crosses the intended biological threshold during early evaluation. BeyondSpring described DUBLIN-4 in June 2026 as a 442-patient confirmatory trial following prior PD-1 inhibitors. Similar sequence logic can guide targeted oncology biologics that retain activity near surviving tumor margins.

Which country CAGRs are profiled in the vascular disrupting agents market?

Country	CAGR
South Korea	11.2%
USA	10.3%
Canada	10.0%
UK	9.9%
Australia	9.8%

How do country-level CAGRs compare in the vascular disrupting agents market?

The five profiled CAGRs span 1.4 percentage points and describe forecast pace without measuring current revenue or installed clinical volume.

• South Korea combines concentrated oncology infrastructure with strong competition for biomarker-ready patients and experienced investigators.
• The United States supports dose-ranging work through specialist networks although center activation remains costly and operationally demanding.
• Canada provides established clinical research capacity but provincial contracting and travel distances restrict access to repeated imaging.
• The United Kingdom combines regulatory reform with specialist centers although pharmacy coordination and imaging availability can delay activation.
• Australia supports early-phase oncology work through established governance routes while geographic distance complicates synchronized multicenter assessments.

Comparable CAGRs can produce different market entry conditions through differences in trial access and regulatory timing.

The full report covers country analysis across North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

Country-wise Analysis

• South Korean metropolitan cancer networks offer dense specialist coverage and rapid coordination across designated research institutions within major urban research corridors and referral systems. MFDS announced in May 2026 that an expedited process targeting 240-day approval and review timelines would take effect on June 1 for selected new drugs and biosimilars. Adoption of vascular disrupting agents in South Korea is estimated to expand at 11.2% CAGR through 2036, attributable to concentrated infrastructure and faster review targets. Intense competition for biomarker-ready patients and experienced oncology teams can constrain enrollment across imaging-intensive trials running at competing metropolitan centers with similar enrollment criteria.
• United States early-phase oncology centers combine perfusion imaging with research pharmacies and cardiac support across national referral networks and large specialist cancer hospitals. FDA began a combination-dose methods project in September 2025 to improve oncology dosage selection through tolerability, exposure and the contribution of each partner drug. In the United States, vascular disrupting agent demand is predicted to advance at 10.3% CAGR through 2036, supported by dose-ranging expertise despite costly center activation. Sponsors also face uneven imaging access and uncertainty about whether early vascular shutdown produces durable survival benefit across repeated combination cycles and geographically dispersed trial sites nationwide.
• Canadian academic oncology networks support monitored infusion studies and advanced tumor imaging through metropolitan centers with specialist safety services and cross-province referral pathways. Health Canada reported in May 2026 that Canada ranked third worldwide and represented four percent of global clinical trial activity, supported by USD 1.1 billion in research investment since 2020. Canada is estimated to post 10.0% CAGR over the forecast period, influenced by established trial capacity and specialist investigators. Provincial contracting delays and long travel distances can restrict patient access to repeated imaging during combination treatment cycles at qualified metropolitan centers during fixed protocol windows.
• United Kingdom early-phase oncology units combine radiology access with research pharmacies and national referral routes for complex pharmacodynamic protocols across commercial and academic centers. MHRA reforms took effect on 28 April 2026 and introduced faster pathways for lower-risk trials plus selected protocol modifications within the revised national framework. The United Kingdom vascular disrupting agents sector is projected to record 9.9% CAGR during the assessment period, aided by specialist capacity and current national regulatory reform. Hospital contracting and limited imaging slots can delay synchronized activation as pharmacy teams coordinate infusion timing with repeated perfusion assessments across participating specialist oncology hospitals.
• Australian oncology programs use established ethics and governance routes for unapproved therapeutic goods across specialist centers coordinating radiology and time-sensitive sample handling. TGA guidance updated in April 2025 confirms that sponsors submit Clinical Trial Notifications alongside ethics and institutional approvals before patient dosing begins. By 2036, Australia is projected to grow at 9.8% CAGR, driven by early-phase capability and established clinical governance. Geographic separation between major centers can disrupt imaging consistency and biospecimen transport across multicenter vascular-disruption protocols requiring synchronized perfusion imaging. National enrollment schedules must also accommodate distant hospitals and limited domestic referral pools during local specialist assessments.

Who are the notable companies in the vascular disrupting agents market?

Oncotelic Therapeutics, Inc., BeyondSpring Inc., Neuphoria Therapeutics Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Sanofi and Abbott Laboratories are the notable companies serving the vascular disrupting agents market.

The vascular disrupting agent (VDA) landscape remains highly concentrated, as no direct VDA has achieved commercial approval to date. Consequently, competitive activity is largely defined by clinical-stage development programs and legacy assets with established clinical evidence. Oncotelic maintains the most prominent direct VDA portfolio, while BeyondSpring's late-stage vasculature-modulating candidate serves as a key clinical benchmark. Neuphoria retains a partnership-driven VDA asset, and several historical programs continue to provide important comparative reference points for efficacy and development strategies.

• Oncotelic holds the notable direct VDA positioning through CA4P (fosbretabulin) and OXi4503, although advancement of both programs remains dependent on funding availability and strategic development partnerships.
• BeyondSpring offers advanced vasculature-modulating comparator with plinabulin, a late-stage microtubule-targeting candidate, while Neuphoria's BNC105 remains available for potential partner-led oncology development.
• Bristol Myers Squibb maintains selected licensing interests related to combretastatin intellectual property, whereas AstraZeneca, Novartis, Sanofi, and Abbott primarily represent historical or legacy comparators rather than active participants in direct VDA development.

Competitive Benchmarking: Vascular Disrupting Agents Market

Company	Exact-market asset evidence	Clinical-stage depth	Development continuity	Geographic Reach
Oncotelic Therapeutics, Inc.	High	Medium	Medium	United States; licensed global rights
BeyondSpring Inc.	Medium	High	High	United States, China and global trial sites
Neuphoria Therapeutics Inc.	High	Medium	Medium	United States; legacy Australian development
Bristol Myers Squibb Company	Medium	Low	Low	Global intellectual-property reach
AstraZeneca PLC	High	Medium	Low	Global legacy trial reach
Novartis AG	High	High	Low	Global legacy trial reach
Sanofi	High	Medium	Low	Global legacy trial reach
Abbott Laboratories	Low	Medium	Low	Global legacy trial reach

Scoring basis: Exact-market asset evidence is High for verified direct VDA ownership or sponsorship, Medium for a patent license or adjacent vasculature-modulating asset and Low for a verified legacy tubulin comparator. Clinical-stage depth is High at Phase III, Medium at Phase I or II and Low for a licensing role without sponsored trials. Development continuity is High for a funded current study, Medium for evaluation or partnership-dependent work and Low for a discontinued program. Geographic reach records the regions documented through company filings or clinical trial registries for each participant.

Key Developments in the Vascular Disrupting Agents Market

• In March 2026, BeyondSpring reported that it was advancing DUBLIN-4 as a global confirmatory Phase III study of plinabulin plus docetaxel following DUBLIN-3 results and discussions with FDA.
• In January 2026, Oncotelic entered a secured convertible-note agreement with Mast Hill Fund for about USD 0.4 million. The agreement included CA4P and OXi4503 among the secured company assets supporting the oncology financing arrangement.
• In September 2025, Neuphoria reported that BNC105 had been evaluated in six clinical trials and would advance through existing or new development partnerships.

Key Players in the Vascular Disrupting Agents Market

Direct and adjacent clinical developers

• Oncotelic Therapeutics, Inc.
• BeyondSpring Inc.

Partnership and licensing participants

• Neuphoria Therapeutics Inc.
• Bristol Myers Squibb Company

Legacy clinical developers

• AstraZeneca PLC
• Novartis AG
• Sanofi
• Abbott Laboratories

Vascular Disrupting Agents Market - Report Scope

Coverage field	Report scope
Market breakdown	By agent type, mechanism of action, application, route of administration, end user and region.
Quantitative Units	USD billion.
Market Definition	Investigational agents designed to damage established tumor vasculature through vascular or endothelial disruption.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	South Korea, USA, Canada, UK, Australia, and 20+ countries included in the full report.
Key Companies Profiled	Oncotelic Therapeutics, Inc., BeyondSpring Inc., Neuphoria Therapeutics Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Sanofi and Abbott Laboratories
Forecast Period	2026 to 2036.
Approach	Primary and secondary research with market triangulation.

Vascular Disrupting Agents Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Vascular Disrupting Agents Market by Segments

Vascular Disrupting Agents Market segmented by agent type:

• Tubulin-binding vascular disrupting agents
  • Combretastatin derivatives
  • Colchicine-site binding agents
• Flavonoid-based vascular disrupting agents
  • Combretastatin A-4 phosphate
  • Flavonoid analogues
• Microtubule-independent agents
  • Vascular-targeting small molecules
  • Endothelial cytoskeleton disruptors
• Other vascular disrupting agents
  • Novel small-molecule agents
  • Investigational vascular disruptors

Vascular Disrupting Agents Market segmented by mechanism of action:

• Microtubule disruption
  • Tubulin polymerization inhibition
  • Cytoskeletal destabilization
• Endothelial cell damage
  • Endothelial cell apoptosis
  • Vascular permeability disruption
• Blood-flow interruption
  • Tumor blood vessel collapse
  • Tumor ischemia induction
• Other mechanisms
  • Vascular occlusion
  • Multi-mechanism agents

Vascular Disrupting Agents Market segmented by application:

• Oncology
  • Solid tumors
  • Metastatic cancer
• Clinical research
  • Clinical trials
  • Combination therapy studies
• Drug discovery and development
  • Preclinical research
  • Novel vascular targeting

Vascular Disrupting Agents Market segmented by route of administration:

• Intravenous
  • Infusion
  • Intravenous bolus
• Oral
  • Oral small-molecule agents
  • Oral capsule formulations
• Other routes
  • Intra-arterial administration
  • Local administration

Vascular Disrupting Agents Market segmented by end user:

• Hospitals and cancer centers
  • Oncology hospitals
  • Comprehensive cancer centers
• Pharmaceutical and biotechnology companies
  • Large pharmaceutical companies
  • Biotechnology companies
• Academic and research institutes
  • University research centers
  • Cancer research institutes
• Contract research organizations
  • Preclinical CROs
  • Clinical CROs

Vascular Disrupting Agents Market by Region:

• North America
  • United States
  • Canada
• Mexico
  • Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • France
  • Nordics
  • Benelux
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan and Baltic States
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union Countries
  • Rest of Middle East and Africa

Research Sources and Bibliography

• ClinicalTrials.gov. (2026, July 24). Trends and Charts on Registered Studies.
• American Cancer Society. (2026, July 8). American Cancer Society reports latest global cancer statistics; cancer cases approach 21 million worldwide, with burden projected to surge 67% by 2050.
• Oncotelic Therapeutics, Inc. (2026, April 15). Form 10-K.
• BeyondSpring Inc. (2026, March 25). Form 10-K.
• ClinicalTrials.gov. (2026, January 23). Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4).
• BeyondSpring Inc. (2026, June 4). BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value.
• Ministry of Food and Drug Safety. (2026, May 28). MFDS Opens a New Era of Innovation in Medical Product Approval and Review (Target: 240-Day Approval).
• USAFood and Drug Administration. (2025, September 30). Statistical Designs and Considerations for Dose Optimization with Drug Combination and Multiple Indication.
• Health Canada. (2026, May 20). Message from the Minister of Health - International Clinical Trials Day.
• Medicines and Healthcare products Regulatory Agency. (2026, April 27). Launch of clinical trial reforms.
• Therapeutic Goods Administration. (2025, April 9). Clinical Trial Notification (CTN) scheme.
• Neuphoria Therapeutics Inc. (2025, September 29). Form 10-K.
• ClinicalTrials.gov. (Legacy record; last registry update posted 2011, record accessed 2026). Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV).
• ClinicalTrials.gov. (Legacy Phase III record; last registry update posted 2020, record accessed 2026). ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1).
• ClinicalTrials.gov. (Legacy Phase I record; last registry update posted 2013, record accessed 2026). Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors.
• ClinicalTrials.gov. (Legacy Phase II comparator record; last registry update posted 2007, record accessed 2026). A Study of ABT-751 in Patients With Colorectal Cancer.
• BeyondSpring Inc. (2026, March 25). BeyondSpring Reports 2025 Year-End Financial Results.
• Oncotelic Therapeutics, Inc. (2026, January 29). Form 8-K.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the vascular disrupting agents market through the 2036 forecast period?
• What clinical condition supports recurring vascular disrupting agent development across oncology programs?
• Which agent type accounts for the largest approved 2026 market share?
• How does mechanism choice influence dosing and repeat-treatment safety decisions?
• Which administration route supports monitored dosing across imaging-led oncology trials?
• How do country conditions change trial activation and commercial entry requirements?
• Which companies retain direct assets or verified legacy development evidence?
• What biological and safety constraints limit wider clinical adoption today?